These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 29954707)

  • 21. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
    [No Abstract]   [Full Text] [Related]  

  • 22. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge.
    Doshi JA; Pettit AR; Stoddard JJ; Zummo J; Marcus SC
    J Clin Psychopharmacol; 2015 Aug; 35(4):442-6. PubMed ID: 26075492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review.
    Rapinesi C; Kotzalidis GD; Mazzarini L; Brugnoli R; Ferracuti S; De Filippis S; Cuomo I; Giordano G; Del Casale A; Angeletti G; Sani G; Girardi P
    Clin Drug Investig; 2019 Aug; 39(8):713-735. PubMed ID: 31152368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in the Use of Long-Acting Injectable Antipsychotics in the Province of Manitoba, Canada.
    Janzen D; Bolton J; Kuo IF; Leong C; Alessi-Severini S
    J Clin Psychopharmacol; 2020; 40(1):6-13. PubMed ID: 31834085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Guidelines on long-acting injectable atypical antipsychotics for first-episode schizophrenia].
    Azorin JM
    Encephale; 2013 Sep; 39 Suppl 2():S121-3. PubMed ID: 24084422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study.
    Llorca PM; Bobes J; Fleischhacker WW; Heres S; Moore N; Bent-Ennakhil N; Sapin C; Loze JY; Nylander AG; Patel MX
    Eur Psychiatry; 2018 Aug; 52():85-94. PubMed ID: 29734130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attitudes of psychiatrists toward antipsychotic depot medication.
    Heres S; Hamann J; Kissling W; Leucht S
    J Clin Psychiatry; 2006 Dec; 67(12):1948-53. PubMed ID: 17194274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.
    Möller HJ
    Drugs; 2007; 67(11):1541-66. PubMed ID: 17661527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study.
    Joo SW; Shon SH; Choi G; Koh M; Cho SW; Lee J
    Eur Neuropsychopharmacol; 2019 Sep; 29(9):1051-1060. PubMed ID: 31362852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN SCHIZOPHRENIA].
    Teitelbaum A; Kodesh A
    Harefuah; 2019 Jul; 158(7):453-457. PubMed ID: 31339245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics.
    Heres S; Lambert M; Vauth R
    Eur Psychiatry; 2014 Nov; 29 Suppl 2():1409-13. PubMed ID: 25455704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Focused Ethnographic Examination of Barriers to Use of Long-Acting Injectable Antipsychotics.
    Robinson DG; Subramaniam A; Fearis PJ; Shi R; Walsh M; Hanna LA; Kane JM
    Psychiatr Serv; 2020 Apr; 71(4):337-342. PubMed ID: 31847736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed.
    Meyer JM
    CNS Spectr; 2017 Dec; 22(S1):14-28. PubMed ID: 29350127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.
    Citrome L
    Expert Rev Neurother; 2017 Oct; 17(10):1029-1043. PubMed ID: 28832262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.
    Correll CU; Citrome L; Haddad PM; Lauriello J; Olfson M; Calloway SM; Kane JM
    J Clin Psychiatry; 2016; 77(suppl 3):1-24. PubMed ID: 27732772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reducing the stigma of long acting injectable antipsychotics - current concepts and future developments.
    Taylor DM; Velaga S; Werneke U
    Nord J Psychiatry; 2018 Sep; 72(sup1):S36-S39. PubMed ID: 30688170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective.
    Rauch AS; Fleischhacker WW
    CNS Drugs; 2013 Aug; 27(8):637-52. PubMed ID: 23780619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
    Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
    J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
    [No Abstract]   [Full Text] [Related]  

  • 40. Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting.
    Kishimoto T; Sanghani S; Russ MJ; Marsh AN; Morris J; Basu S; John M; Kane JM
    Int Clin Psychopharmacol; 2017 May; 32(3):161-168. PubMed ID: 28181959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.